A Phase 1 interventional study of CSL787 and Placebo in Noncystic Fibrosis Bronchiectasis (NCFB), sponsored by CSL Behring. Completed at 3 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-15.
Sponsored by CSL Behring (part of CSL Limited) · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies in Bronchiectasis with a site in United Kingdom — 18 open to participants now, 19 under way, 2 of them phase 3. Bronchiectasis · United Kingdom.
Among the 73 studies in Bronchiectasis with a site in United Kingdom, this one is the 30th largest by enrollment of the 52 interventional ones that give a count, is one of 5 that started in 2020, is one of 4 in phase 1, and was the 46th registered.
404 studies on the registry are indexed under Bronchiectasis; 125 are open to participants now.
Browse Bronchiectasis studies →18 of the 73 studies in Bronchiectasis with a site in United Kingdom are open now. Recruiting first, the newest first:
Richmond Research Institute · Sites in United Kingdom
Ages 18+
AstraZeneca · Sites in United Kingdom, United States, Argentina and 22 more countries
Ages 12+
GlaxoSmithKline · Sites in United Kingdom, United States, Argentina and 9 more countries
Ages 18–85
Papworth Hospital NHS Foundation Trust · Sites in United Kingdom
Ages 18+
University College, London · Sites in United Kingdom
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 93 Bronchiectasis studies recruiting now, 50 (54%) set no upper age limit and 13 (14%) stop at 75 or younger; 12 take children under 18; 26 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 19 · Phase 3 11 · Phase 4 9
First in 2003; this study’s year is marked. 5 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 64 is close to the median of 60 across 263 interventional studies indexed under Bronchiectasis.
Median enrollment 89 across the 52 interventional studies, 80 across the 21 observational. Of the 48 that completed or were terminated, 16 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 73 have an industry lead sponsor. The 10 most frequent:
This study is registered under CSL Behring, one of the names counted as CSL Limited. Under that name alone:
CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.
CSL Limited has 1 study filed under Bronchiectasis — fewer than ten, so there is no comparison to draw.
9 of the studies in Bronchiectasis with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06872892Phase 3Boehringer IngelheimThe AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis | 2027-06-15 |
| NCT03791086University of DundeeThe BRIDGE Study - Bronchiectasis Research Involving Databases, Genomics and Endotyping | 2027-02-01 |
| NCT05846230Boehringer IngelheimClairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine | 2027-03-31 |
| NCT06625944Imperial College LondonExploring How Viral Infections Affect People With Chronic Lung Disease | 2027-04 |
| NCT06931002Imperial College LondonA Rhinovirus Challenge Study to Investigate Exacerbations and Immune Responses in Bronchiectasis | 2027-04-01 |
Add all 9 to your calendar (.ics) → With an account.
Among the 73 studies in Bronchiectasis with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a prospective, multicenter, randomized, double-blind, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and exploratory efficacy of nebulized CSL787 after administrations of single (SAD) ascending doses in healthy subjects and multiple (MAD) ascending doses in subjects with NCFB.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For Part A (SAD) Only:
For Part B (MAD) Only:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Inhalation by mouth of a nebulized aerosol in healthy subjects
Biological: CSL787
Inhalation by mouth of a nebulized aerosol in healthy subjects
Biological: CSL787
Inhalation by mouth of a nebulized aerosol in healthy subjects
Biological: CSL787
Inhalation by mouth of a nebulized aerosol in healthy subjects
Biological: CSL787
Inhalation by mouth of a nebulized aerosol in NCFB subjects
Biological: CSL787
Inhalation by mouth of a nebulized aerosol in NCFB subjects
Biological: CSL787
Inhalation by mouth of a nebulized aerosol in NCFB subjects
Biological: CSL787
Inhalation by mouth of a nebulized aerosol
Drug: Placebo
Human plasma-derived polyvalent immunoglobulin G (IgG) administered via inhalation of an aerosol produced using a nebulizer
Normal saline (0.9% NaCl)
Number of subjects with treatment emergent adverse events (TEAEs) - overall, severity and causality
Time frame: Up to 8 days (healthy volunteers); Up to 21 days (NCFB patients)
Percent of subjects with TEAEs - overall, severity and causality
Time frame: Up to 8 days (healthy volunteers); Up to 21 days (NCFB patients)
Maximum concentration (Cmax) of CSL787 in sputum and serum in healthy subjects
Time frame: Up to 8 days from inhalation
Time of maximum concentration (Tmax) of CSL787 in sputum and serum in healthy subjects
Time frame: Up to 8 days from inhalation
Area under the concentration-time curve from time 0 to 24 hours (AUC0-24h) of CSL787 in sputum and serum in healthy subjects
Time frame: Up to 8 days from inhalation
Area under the concentration-time curve from time 0 to last quantifiable time point (AUC0-last) of CSL787 in sputum and serum in healthy subjects
Time frame: Up to 8 days from inhalation
Area under the concentration-time curve from time 0 extrapolated to infinity (AUC0-inf) of CSL787 in sputum and serum in healthy subjects
Time frame: Up to 8 days from inhalation
Apparent total clearance of the drug (CL/F) of CSL787 in sputum and serum in healthy subjects
Time frame: Up to 8 days from inhalation
Apparent volume of distribution during the elimination phase (V/F) of CSL787 in sputum and serum in healthy subjects
Time frame: Up to 8 days from inhalation
Terminal elimination half-life (T1/2) of CSL787 in sputum and serum in healthy subjects
Time frame: Up to 8 days from inhalation
Cmax of CSL787 in sputum and serum of NCFB subjects
Time frame: On Day 1, after dosing
Tmax of CSL787 in sputum and serum of NCFB subjects
Time frame: On Day 1, after dosing
Ctrough of CSL787 in sputum and serum of NCFB subjects
Time frame: On Day 1, after dosing
AUCtau of CSL787 in sputum and serum of NCFB subjects
Time frame: On Day 1, after dosing
Cmax of CSL787 in sputum and serum of NCFB subjects
Time frame: On Day 14, after last dose
Tmax of CSL787 in sputum and serum of NCFB subjects
Time frame: On Day 14, after last dose
Ctrough of CSL787 in sputum and serum of NCFB subjects
Time frame: On Day 14, after last dose
AUCtau of CSL787 in sputum and serum of NCFB subjects
Time frame: On Day 14, after last dose
T1/2 of CSL787 in sputum and serum of NCFB subjects
Time frame: On Day 14, after last dose
CL/F of CSL787 in sputum and serum of NCFB subjects
Time frame: On Day 14, after last dose
V/F of CSL787 in sputum and serum of NCFB subjects
Time frame: On Day 14, after last dose
Accumulation Ratio (AR) for Cmax of CSL787 in sputum and serum of NCFB subjects
Time frame: On Day 14, after last dose
AR for Ctrough of CSL787 in sputum and serum of NCFB subjects
Time frame: On Day 14, after last dose
AR for AUCtau of CSL787 in sputum and serum of NCFB subjects
Time frame: On Day 14, after last dose
Plan to share: Yes — CSL will consider requests to share Individual Patient Data (IPD) from systematic review groups or bona-fide researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com. Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD. If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.
Supporting information: Study protocol, Statistical analysis plan
Time frame: IPD requests may be submitted to CSL no earlier than 12 months after publication of the results of this study via an article made available on a public website.
Access criteria: Requests may only be made by systematic review groups or bona-fide researchers whose proposed use of the IPD is non-commercial in nature and has been approved by an internal review committee. An IPD request will not be considered by CSL unless the proposed research question seeks to answer a significant and unknown medical science or patient care question as determined by CSL's internal review committee. The requesting party must execute an appropriate data sharing agreement before IPD will be made available.
No publications or documents are linked to this record.
Ran from Dec 2020 to primary completion in Mar 2023, 27 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Immunoglobulins, Intravenous